Catalyst Pharmaceuticals, Inc. (CPRX)

盈利方式

Almost all revenue is net product revenue from selling branded medicines in the United States. Because the patient populations are tiny and the therapies chronic, the model is few patients at a very high annual price per patient, dispensed through a narrow channel: FIRDAPSE and AGAMREE reach patients through a very small group of exclusive specialty pharmacies, coordinated by the company's own Catalyst Pathways support programme, rather than through ordinary pharmacy retail. Revenue is booked net of large gross-to-net deductions — rebates, chargebacks, government programme discounts and patient assistance — so the reported figure is well below list-price sales. A small additional stream comes from licensing FIRDAPSE to sublicensees abroad (KYE in Canada, DyDo in Japan, which launched in January 2025) and from royalties; license and other revenue was only $0.2 million in 2025, against $588.8 million of product revenue.

分部营收

What protects Catalyst is regulatory and legal, not structural: orphan-drug designations, patents, and the specialised infrastructure needed to find and serve patients in diseases that affect very few people. In an ultra-rare indication a rival has to identify the same handful of patients and rebuild the same reimbursement and support machinery, which few bother to do. But the protection has a clock on it. FIRDAPSE's seven-year orphan exclusivity expired on 26 November 2025, leaving only the patents — expiring in 2032, 2034 and 2037 — which are being tested in court: Teva and Lupin settled, while litigation against Hetero was set for trial in March 2026. AGAMREE is licensed rather than owned, so its economics are shared with Santhera. FYCOMPA shows what happens when the protection runs out: revenue fell and promotion stopped. This is a narrow moat built on defensible but finite exclusivity.

Demand has almost nothing to do with the economic cycle. These are chronic therapies for serious rare diseases: patients do not stop taking them in a recession, and volumes are set by how many people are diagnosed, how many start treatment and how many stay on it, not by consumer confidence or industrial activity. What actually moves revenue is disease awareness and diagnosis rates in a population that is hard to find, the pace of new patient starts after a launch, payer coverage decisions, and above all patent and exclusivity events — a generic entry can cut a product's revenue far faster than any recession would.

主要风险

• Dependence on a single lead product — FIRDAPSE generates the clear majority of revenue. The company states that anything impairing FIRDAPSE — a generic entrant, a safety issue, a reimbursement change — would materially damage results, and that it may not identify enough LEMS patients to keep growing, since the size of the diagnosed population is uncertain.
• Generic competition and patent litigation — FIRDAPSE's orphan-drug exclusivity expired on 26 November 2025. The remaining defence is the patent estate (2032, 2034, 2037), which generic filers have challenged: settlements were reached with Teva and Lupin, while litigation against Hetero was scheduled for trial on 23 March 2026. An adverse outcome would open the product to generic entry. FYCOMPA already lost exclusivity and its revenue is declining under generic pressure.
• Distribution through a very small group of specialty pharmacies — The company distributes FIRDAPSE and AGAMREE through a very small group of exclusive specialty pharmacies, primarily AnovoRx, under its Catalyst Pathways programme. Losing one of these partners, or a failure in their operations or credit, would disrupt patient supply and cash collection.
• Reliance on licensors and third-party manufacturers — Catalyst owns no manufacturing. Rights to FIRDAPSE come from BioMarin (now SERB), AGAMREE from Santhera, and FYCOMPA is supplied by Eisai. Supply interruptions, disputes with licensors, or failure by a third-party manufacturer to meet regulatory standards could halt sales.
• Pricing, reimbursement and government policy — Revenue depends on payers accepting very high per-patient prices. The company flags drug-pricing pressure, healthcare cost-containment measures, proposed Most Favored Nation pricing, and tariffs as factors that could reduce the net price it realises.
• Competition in Duchenne muscular dystrophy — AGAMREE competes against established corticosteroids and against gene therapies and other new treatments being developed for Duchenne. The company identifies gene therapy competition as a risk to AGAMREE's commercial trajectory.

The filing does not disclose a percentage of revenue from the largest customers in the material reviewed, so no number is given here. It does state that the concentration is extreme by design: FIRDAPSE and AGAMREE are distributed through a very small group of exclusive specialty pharmacies, primarily AnovoRx, so the company's direct customers are a handful of intermediaries rather than the thousands of pharmacies a conventional drug maker sells to. The economic risk sits one level further out — with the insurers and government programmes that reimburse those prescriptions.